GlobeNewswire: Spark Therapeutics, Inc. Contains the last 10 of 158 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:37:25ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/01/27/2596936/0/en/Spark-Therapeutics-Enters-Into-Strategic-Collaboration-with-Neurochase-for-Use-of-Proprietary-Delivery-Technology-for-CNS-Disorders.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders2023-01-27T14:00:00Z<![CDATA[PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform.]]>https://www.globenewswire.com/news-release/2022/12/12/2572170/0/en/Spark-Therapeutics-Announces-Updated-Phase-1-2-Study-Results-Supporting-the-Durability-of-Investigational-Gene-Therapy-SPK-8011-in-Patients-With-Hemophilia-A.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A2022-12-12T17:00:00Z<![CDATA[PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated gene therapy company today announced updated multi-year results from its Phase 1/2 clinical trial of investigational SPK-8011 for patients with hemophilia A. With up to five years of follow-up, the data showed that a single infusion resulted in sustained factor VIII (FVIII) expression and clinically meaningful reductions in annualized bleed rate (ABR) and annualized FVIII infusion rates (AIRs). These data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, La.]]>https://www.globenewswire.com/news-release/2022/02/23/2390560/0/en/Spark-Therapeutics-Announces-Departure-of-CEO-and-Founder-Jeff-Marrazzo-COO-Ron-Philip-Named-as-Successor.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor2022-02-23T15:29:00Z<![CDATA[Under Jeff Marrazzo’s leadership, Spark launched world’s first FDA-approved gene therapy for a genetic disease. He also spearheaded Spark’s $4.8 billion acquisition by Roche.]]>https://www.globenewswire.com/news-release/2021/12/17/2354448/0/en/Spark-Therapeutics-to-Invest-575M-in-New-500k-Square-Foot-State-of-the-Art-Gene-Therapy-Innovation-Center-on-Drexel-s-University-City-Campus.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus2021-12-17T13:00:00Z<![CDATA[Roche affirms its long-term commitment to Philadelphia as gene therapy center of excellence]]>https://www.globenewswire.com/news-release/2021/11/17/2336862/0/en/Spark-Therapeutics-Updated-SPK-8011-Data-from-Phase-1-2-Study-Shows-Multi-Year-Durable-Factor-VIII-FVIII-Expression-that-Significantly-Reduced-Bleeding-in-Hemophilia-A-Patients.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients2021-11-17T22:01:53Z<![CDATA[Data from Spark Therapeutics’ Phase 1/2 gene therapy study published in New England Journal of Medicine Data from Spark Therapeutics’ Phase 1/2 gene therapy study published in New England Journal of Medicine]]>https://www.globenewswire.com/news-release/2021/10/12/2312443/0/en/Spark-Therapeutics-and-CombiGene-Enter-into-Exclusive-Global-Licensing-Agreement-for-Gene-Therapy-Candidate-CG01.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG012021-10-12T11:30:00Z<![CDATA[PHILADELPHIA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.]]>https://www.globenewswire.com/news-release/2021/07/21/2266633/0/en/Spark-Therapeutics-SPK-8011-Suggests-Stable-and-Durable-Factor-VIII-Expression-in-Largest-Phase-1-2-Gene-Therapy-Study-in-Hemophilia-A-to-Date.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date2021-07-21T14:12:00Z<![CDATA[Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011]]>https://www.globenewswire.com/news-release/2021/04/13/2209116/0/en/Spark-Therapeutics-Enters-Collaboration-with-Senti-Bio-to-Bolster-Industry-Leading-Gene-Therapy-Research-Platform.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform2021-04-13T12:30:00Z<![CDATA[Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver]]>https://www.globenewswire.com/news-release/2021/02/25/2182347/0/en/Spark-Therapeutics-Further-Strengthens-Technical-Expertise-with-Appointment-of-Cynthia-Pussinen-as-Chief-Technical-Officer.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer2021-02-25T12:30:00Z<![CDATA[PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Cynthia Pussinen as chief technical officer (CTO). Cynthia has more than 25 years of experience in the biopharma industry, leading teams in manufacturing, quality, supply chain, formulation development and process sciences. As CTO, she will oversee Spark’s manufacturing and technical operations, including pipeline process development, preclinical and clinical manufacturing, and the commercial manufacturing and distribution of LUXTURNA® (voretigene neparvovec-rzyl).]]>https://www.globenewswire.com/news-release/2021/02/05/2170824/0/en/Spark-Therapeutics-Announces-Preliminary-Data-from-Phase-1-2-Clinical-Trial-of-SPK-8016-in-Hemophilia-A-at-EAHAD-2021-Virtual-Congress.html?f=22&fvtc=4&fvtv=25323Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress2021-02-05T15:51:00Z<![CDATA[Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X1011 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable factor VIII (FVIII) expression at greater than 52 weeks]]>